Tesamorelin (Growth Hormone Releasing Hormone Analog) – TH9507

Product Overview

Tesamorelin is a highly specialized, synthetic analog of Growth Hormone Releasing Hormone (GHRH). Engineered with a specific N-terminal modification, it is designed to resist rapid enzymatic degradation while preserving full GHRH receptor binding affinity. Distinguished by its robust clinical data profile, Tesamorelin is widely utilized in advanced metabolic research to investigate targeted visceral fat reduction, physiological growth hormone pulsatility, and non-alcoholic fatty liver disease (NAFLD) without the suppressive effects of exogenous growth hormone administration.

Technical Specifications

• Molecular Formula: C221H366N72O67S

• Molecular Weight: 5135.85 g/mol

• CAS Number: 218949-48-5

• Sequence Profile: Trans-3-hexenoic acid-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2 (Features a trans-3-hexenoic acid addition for DPP-IV enzymatic resistance)

Mechanism of Action

Tesamorelin exerts its profound lipolytic and metabolic effects by acting upstream in the endocrine axis, preserving the body's natural feedback loops:

• Enzymatic Resistance: The trans-3-hexenoic acid N-terminal modification protects the peptide from rapid degradation by DPP-IV enzymes, offering meaningful stability improvements over native GHRH while allowing for a discrete, physiological GH pulse.

• GHRH Receptor Agonism: Binds to GHRH receptors in the pituitary gland, stimulating the endogenous synthesis and pulsatile release of growth hormone.

• Targeted Lipolysis: The resulting elevation in GH and IGF-1 promotes robust lipolysis through hormone-sensitive lipase activation, selectively targeting and mobilizing visceral adipose tissue (VAT) while largely preserving subcutaneous fat.

• Hepatic Lipid Processing: Restores the GH/IGF-1 axis, which directly influences hepatic lipid metabolism, reducing liver fat content and improving triglyceride profiles.

Primary Research Applications

Tesamorelin is a premier compound for in vitro and animal model studies investigating:

• Targeted Visceral Adiposity Reduction and Lipodystrophy

• Hepatic Steatosis (NAFLD) and Lipid Metabolism

• Preservation of Physiological GH/IGF-1 Endocrine Feedback Loops

• Cognitive Function and Mild Cognitive Impairment (MCI) in aging models

• Cardiovascular Risk Markers and Metabolic Syndrome Management

Storage & Handling

For optimal long-term stability and structural integrity, store unopened lyophilized powder securely refrigerated at 36°F to 46°F (2°C to 8°C) or frozen at -4°F (-20°C). Once reconstituted, the solution must be kept strictly refrigerated at 36°F to 46°F (2°C to 8°C) and utilized within 14 days to preserve the peptide sequence.

⚠️ Important Disclaimer for Carbon Nova Labs Customers: All information provided is for educational and reference purposes only. Tesamorelin is sold strictly for laboratory research use only. This compound is not approved by the FDA for human consumption, therapeutic use, or clinical application. Ensure compliance with all institutional safety protocols and consult qualified professionals before conducting research.